Stephane Bancel, Chief Executive Officer at Moderna, Inc. (MRNA), sold 53,944 shares at $122.01 ($6.6M) on 2023-06-28, disclosed to the SEC on 2023-06-30.
Scheduled sale ($6.6M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $120.39 | 2,278 | $274K | 4.2% |
| 2 | $120.39 | 2,278 | $274K | 4.2% |
| 3 | $121.40 | 11,417 | $1.4M | 21.1% |
| 4 | $121.40 | 11,417 | $1.4M | 21.1% |
| 5 | $122.01 | 13,094 | $1.6M | 24.4% |
| 6 | $122.01 | 13,094 |
| $1.6M |
| 24.4% |
| 7 | $123.05 | 366 | $45K | 0.7% |
| Total | $121.62 avg | 53,944 | $6.6M | 100% |
| Filing → |
| MRNA | SELL | 2024-02-16 | $4.7M | — | Filing → |
| MRNA | SELL | 2023-06-23 | $19.3M | — | Filing → |
| MRNA | SELL | 2023-06-16 | $20.4M | — | Filing → |